Gritstone bio Inc
Change company Symbol lookup
Select an option...
GRTS Gritstone bio Inc
QTWO Q2 Holdings Inc
DNAB Social Capital Suvretta Holdings Corp II
UPST Upstart Holdings Inc
GILT Gilat Satellite Networks Ltd
LAIXY LAIX Inc
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
OXBR Oxbridge Re Holdings Ltd
NVO Novo Nordisk A/S
JNJ Johnson & Johnson
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Gritstone bio, Inc. is a biotechnology company. The Company discover, develop, manufacture and deliver next generation cancer and infectious disease immunotherapy candidates by vaccine vectors, self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. The Company has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate that are collaborating on with Gilead Sciences, Inc. The Company’s product candidates include GRT-C907 (ChAd)/R908 (samRNA), GRT- C909 (ChAd)/R910 (samRNA), GRT-C909 (ChAd)/R910 (samRNA), GRT-R914 (samRNA), GRT-R912 (samRNA) and GRT-R918 (samRNA).

Closing Price
$2.57
Day's Change
0.04 (1.58%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.72
Day's Low
2.55
Volume
(Average)
Volume:
511,650

10-day average volume:
561,584
511,650

Twist Bioscience to Report Fiscal 2022 Third Quarter Financial Results on Friday, August 5, 2022

8:00 am ET July 18, 2022 (BusinessWire) Print

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2022 third quarter ended June 30, 2022, before the opening of the market on Aug. 5, 2022. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Investor Relations section under the "Company" tab at www.twistbioscience.com.

The conference call will be webcast live through the Investor Relations section under the "Company" tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company's Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005266/en/

SOURCE: Twist Bioscience Corporation">

For Twist Bioscience: 
Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com
comtex tracking

COMTEX_410462258/1006/2022-07-18T08:00:03

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.